



**Neurology
Standing Committee Meeting
April 4-5, 2016**

National Quality Forum
Executive Building
1030 15th Street, NW
9th Floor Conference Center
Washington, DC 20005
(202) 783-1300

Please use the following information to access the conference call line and webinar:

Speaker dial-in number: 1 (888) 802-7237

Public dial-in number: 1 (877) 303-9138

Webinar Link: <http://nqf.commpartners.com>

Webinar Meeting ID Day 1: 405045

Webinar Meeting ID Day 2: 172613

AGENDA

Day 1: April 4

8:00am **Continental Breakfast**

8:30am **Welcome**

David Knowlton, MA, Co-Chair

David Tirschwell, MD, MSc, Co-Chair

Margaret Terry, PhD, RN, Senior Director, NQF

Christy Skipper, MS, Project Manager, NQF

8:40am **Introductions and Disclosures of Interest**

Ann Hammersmith, JD, General Counsel, NQF

9:00am **Project Introduction and Overview of Evaluation Process**

Margaret Terry

Christy Skipper

10:15am **Consideration of Candidate Measures**

- 0661: Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients who Received Head CT or MRI Scan Interpretation Within 45 minutes of ED Arrival (Centers for Medicare and Medicaid Services/Mathematica/The Lewin Group)

- 11:00am **Break**
- 11:10am **Overview of eMeasures**
Ann Phillips, MHA, Project Manager, NQF
- 11:25am **Consideration of Candidate Measures (Continued)**
- 0434: STK-01: Venous Thromboembolism (VTE) Prophylaxis (The Joint Commission)
 - 0435: STK-02: Discharged on Antithrombotic Therapy (The Joint Commission)
 - 2832: STK-02: Discharged on Antithrombotic Therapy (The Joint Commission)
- 12:30pm **NQF Member and Public Comment**
- 12:40pm **Lunch**
- 1:10pm **Consideration of Candidate Measures (Continued)**
- 0439: STK-06: Discharged on Statin Medication (The Joint Commission)
 - 2836: STK-06: Discharged on Statin Medication (The Joint Commission)
 - 0437: STK-04: Thrombolytic Therapy (The Joint Commission)
 - 2834: STK-04: Thrombolytic Therapy (The Joint Commission)
 - 0438: STK-05: Antithrombotic Therapy By End of Hospital Day Two (The Joint Commission)
 - 2835: STK-05: Antithrombotic Therapy By End of Hospital Day Two (The Joint Commission)
 - 0436: STK-03: Anticoagulation Therapy for Atrial Fibrillation/Flutter (The Joint Commission)
 - 2833: STK-03: Anticoagulation Therapy for Atrial Fibrillation/Flutter (The Joint Commission)
- 3:15pm **Break**
- 3:30pm **Consideration of New Candidate Measures (Continued)**
- 0441: STK-10: Assessed for Rehabilitation (The Joint Commission)
 - 2837: STK-10: Assessed for Rehabilitation (The Joint Commission)
 - 2863: CSTK-06: Nimodipine Treatment Administered (The Joint Commission)
 - 2864: CSTK-01: National Institutes of Health Stroke Scale (NIHSS) Score Performed for Ischemic Stroke Patients (The Joint Commission)
- 5:00pm **NQF Member and Public Comment**

5:15 pm **Adjourn**

Day 2: April 5

8:00am **Continental Breakfast**

8:30am **Welcome, Recap of Day 1**

David Knowlton

David Tirschwell

8:40am **Consideration of Candidate Measures (Continued)**

- 2865: CSTK-02: Modified Rankin Score (mRS) at 90 Days (The Joint Commission)
- 2866: CSTK-03: Severity Measurement Performed for Subarachnoid Hemorrhage (SAH) and Intracerebral Hemorrhage (ICH) Patients (Overall Rate) (The Joint Commission)
- 2876: Hospital 30-day, all-cause, risk-standardized mortality rate (RSMR) following acute ischemic stroke hospitalization with claims-based risk adjustment for stroke severity (Centers for Medicare and Medicaid/Yale Core)
- 2877: Hybrid hospital 30-day, all-cause, risk-standardized mortality rate (RSMR) following acute ischemic stroke with risk adjustment for stroke severity (Centers for Medicare and Medicaid/Yale Core)

10:45am **Break**

11:00am **Consideration of Candidate Measures (Continued)**

- 1814: Counseling for Women of Childbearing Potential with Epilepsy (American Academy of Neurology)
- 0507: Diagnostic Imaging: Stenosis Measurement in Carotid Imaging Reports (ACR)
- 1952: Time to Intravenous Thrombolytic Therapy (American Heart Association/American Stroke Association)

12:30pm **NQF Member and Public Comment**

12:45pm **Lunch**

1:05pm **Consideration of Candidate Measures (Continued)**

- 2111: Antipsychotic Use in Persons with Dementia (Pharmacy Quality Alliance)
- 2872: Dementia – Cognitive Assessment (Physician Consortium for Performance Improvement)

- 2870: Overuse of Opioid Containing Medications for Primary Headache Disorders (American Academy of Neurology)

2:10pm **Additional Discussion Topics – Harmonization, Gaps, etc.**

2:40pm **NQF Member and Public Comment**

2:50pm **Next Steps/Committee Timeline**
Christy Skipper

3:00pm **Adjourn**